Navigation Links
Genzyme and Sunway to Collaborate on Gene Therapy Program in China
Date:10/25/2007

CAMBRIDGE, Mass., and SHANGHAI, China /PRNewswire-FirstCall/ -- Genzyme Corp. (Nasdaq: GENZ) and Sunway Biotech Co. Ltd. announced today that they will collaborate to manufacture, develop, and commercialize the experimental gene therapy Ad2/HIF-1a in China. The product is Genzyme's most advanced gene therapy candidate and is currently in Phase 2 clinical testing in the United States and Europe.

Sunway is a privately-held, Shanghai-based biotechnology company founded in 1995. It is one of only two companies in the world to have successfully developed and commercialized a gene therapy product. Sunway's H101, an adenovirus agent for the treatment of head and neck cancer, was approved in China in 2005. With strong technical, regulatory, manufacturing and clinical expertise, Sunway is working towards becoming a preferred partner to western biopharmaceutical firms looking to develop and commercialize products in China.

Genzyme has been a gene therapy pioneer, and the company's commitment to the field remains strong, with a broad clinical and pre-clinical research program in the areas of cardiovascular disease, Parkinson's disease and other neurodegenerative diseases, ocular disease, and lysosomal storage disorders. Additionally, Genzyme has a gene therapy manufacturing facility in San Diego, California.

Ad2/HIF-1a is an engineered form of the HIF-1a gene designed to promote the growth of new blood vessels and improve circulation in the limbs of patients with peripheral arterial disease. Genzyme is currently conducting a Phase 2 clinical trial of Ad2/HIF-1a involving more than 300 patients at 40 U.S. and European medical centers. The trial is examining the safety and effectiveness of locally delivered Ad2/H
'/>"/>

SOURCE Genzyme Corp.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Cytochroma settles lawsuit with Genzyme
2. Genzyme sues former Bone Care employees
3. Genzyme acquistion of Bone Care approved, significant impact forecast
4. GE, St. Jude to collaborate on visualization technology
5. GE Healthcare, MobileAccess to collaborate on hospital wireless
6. GE Healthcare, Harvard medical school to collaborate on nervous system research
7. Madison, Milwaukee med schools to collaborate on tech transfer
8. EraGen collaborates with Emory University on HIV detection system
9. The Genesis of Gendicine: The Story Behind the First Gene Therapy
10. TomoTherapy reports 86% revenue jump, $131M net loss in Q1
11. TomoTherapy opens technical training center
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/30/2015)... N.J. , April 30, 2015  Roka Bioscience, ... focused on providing advanced testing solutions for the detection ... results for the first quarter of 2015 on May ... Roka Bioscience will also host a conference ... 2015 to discuss its first quarter financial results. During ...
(Date:4/30/2015)... 2015 Nitto Avecia, a leading ... increased capacity and production capability to serve biotechnology ... and service fulfillment continues to drive Nitto Avecia ... throughput capacities. , In Fall 2014, ... process equipment at its Milford, MA facility, which ...
(Date:4/30/2015)...  The Paul G. Allen Family Foundation announced today ... six groups of researchers with projects at the frontier ... growing mature human brain cells in the laboratory. The ... over three years.  "This new cohort ... significant because the field of neuronal maturation is at ...
(Date:4/30/2015)... April 30, 2015 WuXi PharmaTech (Cayman) Inc. ... leading global contract R&D services provider, today announced that ... proposal letter, dated April 29, 2015, from a consortium ... (the "Chairman"), founder, chairman and chief executive officer of ... that proposes a transaction (the "Transaction") involving the acquisition ...
Breaking Biology Technology:Roka Bioscience to Report First Quarter 2015 Financial Results On May 7, 2015 2Biotechnology Manufacturer Nitto Avecia Expands Capacity to Meet Client Demand 2The Paul G. Allen Family Foundation Awards $7.5 Million To Study Brain Cell Growth And Development 2The Paul G. Allen Family Foundation Awards $7.5 Million To Study Brain Cell Growth And Development 3The Paul G. Allen Family Foundation Awards $7.5 Million To Study Brain Cell Growth And Development 4The Paul G. Allen Family Foundation Awards $7.5 Million To Study Brain Cell Growth And Development 5WuXi PharmaTech Announces Receipt of Proposal 2WuXi PharmaTech Announces Receipt of Proposal 3WuXi PharmaTech Announces Receipt of Proposal 4WuXi PharmaTech Announces Receipt of Proposal 5WuXi PharmaTech Announces Receipt of Proposal 6
... Annual Observance To Draw Attention To ,The Sneak Thief ... an effort to combat one of the,main causes of ... World Glaucoma Patient Organization have announced the first annual,World ... The day will be marked,by awareness and educational events ...
... and CLAREMONT, Calif., Jan. 30 /Xinhua-PRNewswire-FirstCall/ --,Kiwa Bio-Tech ... the volume of bio-enhanced feed products sold during ... quarter of 2007 and increased,25% over the same ... Feed Co., Ltd. ("Kiwa Tianjin") is a joint-venture ...
... Tengion Inc., a clinical,stage regenerative medicine company focused ... that Steven Nichtberger, M.D.,President and Chief Executive Officer, ... Biotechnology and Medical Device Conference on,Tuesday, February 5, ... be held at,the Grand Hyatt Hotel in New ...
Cached Biology Technology:World Glaucoma Day Set for March 6th 2Kiwa Bio-Tech Animal Feed Volume Increased 25% in Fourth Quarter of 2007 2
(Date:4/14/2015)... 14, 2015  HYPR Corp. today announced it ... ) Alliance tm , an industry consortium transforming ... to share technology and collaborate to deliver open ... more secure and private, and easier to use. ... that protects sensitive user information and eliminates the ...
(Date:4/9/2015)... 2015 Synaptics Inc. (NASDAQ: SYNA ), a ... it will report financial results for the third quarter ... the close of market. The company will host a ... p.m. PT (5:00 p.m. ET), during which management may ... the live call, analysts and investors should dial 888-438-5524 ...
(Date:4/2/2015)... , April 2, 2015 ... Q1 2015 attributed to somewhat higher than 125 MSEK. ... the year-end report 2014 that revenues for Q1 2015 ... the company reported for Q4 2014. The operating result ... be negative. The complete interim report will as previously ...
Breaking Biology News(10 mins):HYPR Corp. Joins the FIDO Alliance 2HYPR Corp. Joins the FIDO Alliance 3Synaptics to Report Third Quarter Results on April 23 2Fingerprint Cards Revises Revenues for Q1 2015 2
... risks posed by pharmaceuticals are not enough to protect ... of Gothenburg (Sweden) who is calling for better environmental ... the combined effects of different drugs to reflect the ... Brosch from the Department of Plant and Environmental Sciences ...
... of scientists from Singapore led by the Genome Institute ... Cell Biology (IMCB), two biomedical research institutes of ... discovered the most important genes in human embryonic stem ... stem cells work. Their research, published in top scientific ...
... National Laboratory researcher Bette Korber is part of an ... the first human trial of a mosaic HIV vaccine ... the virus that causes AIDS by attempting to address ... design: the virus,s extensive genetic diversity. The team ...
Cached Biology News:Environmental risk assessment of pharmaceuticals inadequate 2Singapore scientists first to perform genome-wide study of human stem cells 2Consortium to design human trials of mosaic HIV vaccine 2
Rabbit polyclonal to hCG ( Abpromise for all tested applications). entrezGeneID: 1081 SwissProtID: P01215...
Anti-HumanLactoferrin...
Rabbit monoclonal [EP881Y] to EEF2K ( Abpromise for all tested applications). Antigen: Synthetic peptide corresponding to residues in the C-terminal of human EEF2K. Entrez GeneID: 29904 S...
ICAD Purified Anti-Mouse clone Polyclonal, Isotype Rabbit Ig, 200 µl Consult technical datasheet for details....
Biology Products: